https://scholars.lib.ntu.edu.tw/handle/123456789/434631
標題: | Application of rituximab to hepatitis C-positive, ABO-incompatible renal transplantation | 作者: | MENG-KUN TSAI CHING-YAO YANG MING-SHIOU WU PO-HUANG LEE |
公開日期: | 2009 | 出版社: | Wichtig Editore s.r.l. | 卷: | 32 | 期: | 5 | 起(迄)頁: | 308-309 | 來源出版物: | International Journal of Artificial Organs | 摘要: | A safety issue has been noted in applying rituximab to renal transplant patients with HCV infection, as a hepatitis C virus (HCV) flare-up and lethal cholestatic hepatitis C occurred in a renal transplant patient treated with rituximab for lymphoproliferative disorder. As double-filtration plasmapheresis (DFPP) and cyclosporine were reported to reduce hepatitis C viremia, we performed ABO-incompatible renal transplantation in two patients with positive HCV RNA by using rituximab, DFPP and cyclosporine-based immunosuppressant. The HCV RNA level was 3.3 × 105 IU/mL for Case 1 and 1.2 × 103 IU/mL for Case 2 before DFPP. After DFPP and renal transplantation, Case 1 had stable ALT levels and a transient decrease in HCV RNA to 7.9 × 104 IU/mL at 1 month followed by a gradual increase to 7.6 × 106 at 12 months, but Case 2 had a dramatic and persistent elevation of HCV RNA to 7.7 × 106 from 1 week to 12 months accompanied by elevated ALT levels. The serum creatinine levels were 1.5 mg/dL for Case 1 and 1.9 mg/dL for Case 2 at 12 months. Although cholestatic hepatitis C did not occur in our patients, who received rituximab for ABO-incompatible renal transplantation, the antiviral effect of cyclosporine and DFPP did not seem evident. ? Wichtig Editore, 2009. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-70149109383&doi=10.1177%2f039139880903200508&partnerID=40&md5=7bfb712fa60ff7cef6bd77e2266d4db1 https://scholars.lib.ntu.edu.tw/handle/123456789/434631 |
ISSN: | 0391-3988 | DOI: | 10.1177/039139880903200508 | SDG/關鍵字: | Patient monitoring; Patient treatment; RNA; ABO-incompatible renal transplantation; Anti-viral effects; Hepatitis C; Hepatitis C virus; Immunosuppressants; Renal transplantation; Renal transplants; Rituximab; Safety issues; Virus infection; Viruses; alanine aminotransferase; antivirus agent; creatinine; cyclosporin; lamivudine; methylprednisolone; mycophenolic acid 2 morpholinoethyl ester; rapamycin; rituximab; virus RNA; acute graft rejection; adult; alanine aminotransferase blood level; article; blood group ABO incompatibility; case report; cholestatic hepatitis; creatinine blood level; hepatitis B; hepatitis C; human; kidney disease; kidney graft rejection; kidney transplantation; male; nonhuman; plasmapheresis; viremia |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。